SL
BBIO icon

Salomon & Ludwin’s BridgeBio Pharma BBIO Stock Holding History

Salomon & Ludwin’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73K Hold
50
– – ﹤0.01% 1881
2026
Q1 		$3.66K Hold
50
– – ﹤0.01% 1839
2025
Q4 		$3.67K Hold
50
– – ﹤0.01% 1884
2025
Q3 		$2.64K Buy
+50
New +$2.44K ﹤0.01% 1929

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Salomon & Ludwin's BBIO Position: Q2 2026 in Review

Salomon & Ludwin held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 50 shares worth $3.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

Salomon & Ludwin first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Salomon & Ludwin held 50 shares of BridgeBio Pharma worth $3.73K as of Q2 2026.
  • Salomon & Ludwin left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1881 holding.
  • Salomon & Ludwin first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.